Top Page
Cardinal Health
(NYSE:CAH)
Cardinal Health (CAH) vs. SPDR S&P 500 ETF (SPY)
Cardinal Health Business Overview & Revenue Model
Cardinal Health Key Performance Indicators (KPIs)
Shows profitability across different business units, highlighting which areas drive earnings and where there might be challenges or opportunities for growth.
Main Street DataCardinal Health Earnings Call Summary
Cardinal Health Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 234.31B | 222.58B | 226.83B | 204.98B | 181.33B | 162.47B |
| Gross Profit | 8.59B | 8.17B | 7.41B | 6.89B | 6.48B | 6.78B |
| EBITDA | 3.26B | 3.11B | 1.96B | 1.44B | 55.00M | 1.29B |
| Net Income | 1.59B | 1.56B | 852.00M | 330.00M | -938.00M | 611.00M |
Balance Sheet | ||||||
| Total Assets | 55.23B | 53.12B | 45.12B | 43.35B | 43.88B | 44.45B |
| Cash, Cash Equivalents and Short-Term Investments | 4.59B | 3.87B | 5.13B | 4.08B | 4.72B | 3.41B |
| Total Debt | 9.03B | 9.35B | 5.61B | 5.18B | 5.80B | 6.71B |
| Total Liabilities | 57.96B | 55.76B | 48.33B | 46.31B | 44.58B | 42.66B |
| Stockholders Equity | -2.88B | -2.78B | -3.21B | -2.96B | -709.00M | 1.79B |
Cash Flow | ||||||
| Free Cash Flow | 4.45B | 1.85B | 3.25B | 2.36B | 2.73B | 2.03B |
| Operating Cash Flow | 5.02B | 2.40B | 3.76B | 2.84B | 3.12B | 2.43B |
| Investing Cash Flow | -5.66B | -5.61B | -1.85B | -454.00M | 567.00M | -378.00M |
| Financing Cash Flow | 2.38B | 1.95B | -847.00M | -3.05B | -2.46B | -1.32B |
Cardinal Health Technical Analysis
Cardinal Health Risk Analysis
Cardinal Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $68.63B | 44.47 | 129.89% | 0.62% | 9.31% | 5.92% | |
72 Outperform | $104.69B | 33.58 | ― | 0.36% | 17.23% | 66.17% | |
69 Neutral | $8.43B | 22.75 | 11.39% | ― | 3.51% | 29.65% | |
66 Neutral | $2.98B | 14.04 | 12.05% | ― | 0.63% | 4.23% | |
65 Neutral | $46.41B | 29.49 | ― | 1.04% | 4.37% | 28.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
38 Underperform | $269.94M | ― | -184.47% | ― | -37.09% | -2639.44% |
Cardinal Health Corporate Events
Cardinal Health, Inc., headquartered in Ohio, is a global healthcare services and products company that provides pharmaceuticals and medical products to various healthcare facilities, enhancing supply chain efficiency and integrated care coordination. In its latest quarterly earnings report, Cardinal Health announced a 22% increase in revenue, reaching $64 billion, driven by growth in branded and specialty pharmaceutical sales. The company’s GAAP operating earnings rose by 18% to $668 million, while non-GAAP operating earnings increased by 37% to $857 million, primarily due to acquisitions and increased contributions from pharmaceutical products. The Pharmaceutical and Specialty Solutions segment saw a 23% revenue increase, while the Global Medical Products and Distribution segment grew by 2%. Cardinal Health’s management remains optimistic about future growth, with expectations of continued demand for its products and services, despite potential challenges from regulatory changes and market conditions.
On October 30, 2025, Cardinal Health reported a 22% increase in first-quarter fiscal year 2026 revenues, reaching $64 billion. The company’s non-GAAP operating earnings rose 37% to $857 million, driven by growth across all five operating segments. The company raised its fiscal 2026 non-GAAP EPS guidance and adjusted free cash flow outlook, reflecting strong financial performance and strategic execution. Cardinal Health also announced the anticipated completion of its acquisition of Solaris Health in early November, which is expected to bolster its market position.
The most recent analyst rating on (CAH) stock is a Buy with a $190.00 price target. To see the full list of analyst forecasts on Cardinal Health stock, see the CAH Stock Forecast page.
On October 7, 2025, Cardinal Health entered into a new 364-Day Credit Agreement with Bank of America, allowing access to $1 billion of revolving credit until October 6, 2026. This agreement supports general corporate purposes and backs the company’s commercial paper program, with conditions including a financial covenant requiring a Consolidated Net Leverage Ratio of no greater than 3.75 to 1.00.
The most recent analyst rating on (CAH) stock is a Buy with a $190.00 price target. To see the full list of analyst forecasts on Cardinal Health stock, see the CAH Stock Forecast page.
On September 30, 2025, Cardinal Health Funding, LLC, a subsidiary of Griffin Capital, and several financial institutions including Wells Fargo and Bank of America, entered into a First Amendment to extend the term of their receivables purchase agreement to September 28, 2028. This amendment aims to maintain the company’s financial flexibility and strengthen its position by ensuring continued access to financing, which is crucial for its operations and relationships with stakeholders.
The most recent analyst rating on (CAH) stock is a Hold with a $165.00 price target. To see the full list of analyst forecasts on Cardinal Health stock, see the CAH Stock Forecast page.
Study Overview: The study titled Real-world Study of Patients With Human Papillomavirus-positive Recurrent/ Metastatic Oropharyngeal Squamous Cell Carcinoma Treated With First Line Pembrolizumab or Nivolumab With or Without Chemotherapy aims to evaluate the effectiveness of pembrolizumab and nivolumab in treating HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). This study is significant as it provides real-world evidence to compare with clinical trial data, enhancing the understanding of treatment benefits and informing future research.
Cardinal Health’s latest earnings call conveyed a generally positive sentiment, underscored by robust financial performance and strategic growth initiatives. The company reported strong operating earnings and EPS growth, alongside significant advancements in its business segments. However, challenges such as increased SG&A expenses and tariff impacts were also acknowledged, though the overall outlook remains optimistic.
On August 27, 2025, Cardinal Health completed a public offering of $1 billion in notes, with proceeds intended to fund part of its proposed acquisition of Solaris Health. If the acquisition is not completed by August 12, 2026, or if Cardinal Health decides not to pursue it, the company will be required to redeem the notes at a premium.
The most recent analyst rating on (CAH) stock is a Hold with a $155.00 price target. To see the full list of analyst forecasts on Cardinal Health stock, see the CAH Stock Forecast page.
On August 13, 2025, Cardinal Health entered into an underwriting agreement with major financial institutions for the sale of $1 billion in notes, consisting of $600 million in 4.500% Notes due 2030 and $400 million in 5.150% Notes due 2035. This financial maneuver is part of Cardinal Health’s strategy to optimize its capital structure, potentially impacting its market positioning and offering implications for investors and stakeholders in terms of financial stability and growth prospects.
The most recent analyst rating on (CAH) stock is a Hold with a $110.00 price target. To see the full list of analyst forecasts on Cardinal Health stock, see the CAH Stock Forecast page.
Cardinal Health is a global distributor of pharmaceuticals and medical products, operating in the healthcare sector with a focus on providing innovative solutions to improve healthcare delivery. The company is known for its extensive distribution network and commitment to enhancing patient care through its diverse range of services.
On August 12, 2025, Cardinal Health announced its fourth quarter and fiscal year 2025 financial results, reporting a relatively flat revenue of $60.2 billion for the fourth quarter. However, excluding the impact of a contract expiration, revenue increased by 21%. The company also reported a significant increase in non-GAAP operating earnings and EPS, driven by strong performance across its segments. Additionally, Cardinal Health raised its fiscal year 2026 non-GAAP EPS guidance and announced the acquisition of Solaris Health, a leading urology management services organization, indicating strategic growth and expansion in its specialty solutions segment.
The most recent analyst rating on (CAH) stock is a Hold with a $110.00 price target. To see the full list of analyst forecasts on Cardinal Health stock, see the CAH Stock Forecast page.